Medtech Investors Gain When The Compass Points To Patients
Seasoned business developer and investor Oern Stuge has worked with the very biggest in medtech in a career spanning over three decades. He bemoans the harm that European policymakers are doing to the one-time capital of the world of medtech innovation. But on the other hand, he knows that the best ideas have a habit of succeeding, regardless of geography.
You may also be interested in...
CEO Perspectives: COVID Impacts On Supply Chain, Digital, At-Home Care, And Medtech’s Place In ‘Food Chain’
CEOs of major medtechs Medtronic, BD, J&J/Ethicon, Edwards Lifesciences, Stryker and Olympus Corp. discuss how the pandemic has shaken up the industry and redefined their companies’ strategies from supply chain and digital uptake to ambulatory and at-home care.
The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.
As the health care sector moves from linear to circular, medtechs, providers and patients all have roles to play in ensuring that current strategies, practices and behaviors contribute to guarantee a sustainable future. Part one of a short series on this theme looks as best practice for providers.